Abstract 353P
Background
To date, there is limited information on Indian oncologists' views and experiences of geriatric oncology. This study aimed to explore the views of Indian oncologists regarding the perception of, and barriers to the incorporation of geriatric screening tools, GA and collaboration with geriatricians in routine clinical practice.
Methods
This was an anonymized cross-sectional survey. The online survey, based on a literature review and expert opinion, comprised 12 questions covering: (i) respondent characteristics, clinical practice environment and patient population; (ii) challenges and treatment decision-making factors in the management of older patients with cancer; and (iii) benefits of and barriers to the implementation of GA or geriatrician review in cancer care for older patients. Qualitative variables were reported as numbers (N) and percentages. Statistical analyses were performed using χ 2 or Fisher’s exact test. Results were considered statistically significant with p < 0.05. Statistical analyses were conducted using SPSS software (version 20).
Results
Between March 2019 and June 2019, 100 answers were collected. Only 74 centres (48%) had a geriatrics department and a mere 21 (14%) medical oncology departments had a person dedicated to GO. The vast majority (n = 100; 88%) had the perception that the number of elderly patients with cancer seen in clinical practice had increased. Eighteen (12%) oncologists had specific protocols and geriatric scales were used at 55 (31%) centres. Almost all (91%) claimed not to apply special management practices using specific tools for every geriatric patient. There was agreement that GO afforded certain potential advantages. Finally, 99% of the oncologists surveyed believed it and that training in GO had to be improved.
Conclusions
From the nationwide survey, we conclude that there is currently no defined care structure for elderly cancer patients. There is an increasing perception of the need for training in GO. This survey reflects a reality in which specific needs are perceived.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tata Memorial Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
253P - Non-Epithelial Tumours of Ovary, An Experience from Qatar
Presenter: Ammar Madani
Session: e-Poster Display Session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
271P - Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
Presenter: Cheng Hsu Wang
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session